JP2002263185A - Medicine administration system and method and medicine administration device - Google Patents
Medicine administration system and method and medicine administration deviceInfo
- Publication number
- JP2002263185A JP2002263185A JP2001068526A JP2001068526A JP2002263185A JP 2002263185 A JP2002263185 A JP 2002263185A JP 2001068526 A JP2001068526 A JP 2001068526A JP 2001068526 A JP2001068526 A JP 2001068526A JP 2002263185 A JP2002263185 A JP 2002263185A
- Authority
- JP
- Japan
- Prior art keywords
- medication
- management device
- network
- schedule
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 559
- 229940079593 drug Drugs 0.000 title claims abstract description 540
- 238000000034 method Methods 0.000 title claims description 37
- 230000007246 mechanism Effects 0.000 claims abstract description 71
- 238000001514 detection method Methods 0.000 claims description 74
- 230000000694 effects Effects 0.000 claims description 18
- 238000012546 transfer Methods 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 abstract description 4
- 238000007726 management method Methods 0.000 description 100
- 230000006870 function Effects 0.000 description 32
- 230000005856 abnormality Effects 0.000 description 21
- 238000012545 processing Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 208000036647 Medication errors Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 101100116283 Arabidopsis thaliana DD11 gene Proteins 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
Landscapes
- Medical Treatment And Welfare Office Work (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、患者の身体に装着
した投薬装置を遠隔地からの指示により動作させて投薬
を行う投薬システムと投薬方法に関する。また、遠隔地
からの指示により動作される投薬装置に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a dosing system and a dosing method in which a dosing device mounted on a patient's body is operated by an instruction from a remote place to perform dosing. Also, the present invention relates to a medication device operated by an instruction from a remote place.
【0002】[0002]
【従来の技術】慢性疾患では、患者に対して継続的に薬
剤を投与する必要がある。例えば、糖尿病では、インシ
ュリンを所定時間毎に投与する必要があるが、その都度
医療機関に出向いて注射を受けることは困難であるた
め、一般に、患者は自分でインシュリンの注射を行って
いる。2. Description of the Related Art In chronic diseases, it is necessary to continuously administer drugs to patients. For example, in the case of diabetes, it is necessary to administer insulin every predetermined time, but it is difficult to go to a medical institution and receive an injection each time. Therefore, generally, a patient injects insulin by himself.
【0003】[0003]
【発明が解決しようとする課題】慢性疾患では、長期間
に渡って、患者が自分で薬剤を投与する必要がある。短
期間であれば、忘れずに所定時刻に薬剤を投与できる
が、投与機関が長期に渡ると、投与を忘れてしまう可能
性が高くなる。本発明は、患者が自分で薬剤を投与する
必要がある場合に、確実に薬剤を投与できるようにする
ことを目的とする。In a chronic disease, a patient needs to administer a drug himself for a long period of time. In a short period, the medicine can be administered at a predetermined time without forgetting. However, if the administration institution is extended, the possibility of forgetting the administration is increased. An object of the present invention is to ensure that a patient can administer a drug when it is necessary to administer the drug.
【0004】[0004]
【課題を解決するための手段】請求項1の発明は、投薬
管理装置と無線端末を備えた投薬装置とがネットワーク
を介してデータを送受信可能であり、前記投薬管理装置
は、前記投薬装置の投薬スケジュールを持つ投薬計画保
持手段と、前記投薬スケジュールが指示する投薬時間に
なるとネットワークを介して前記投薬装置へ投薬を指示
する投薬指示手段とを有し、前記投薬装置は、患者の被
投薬部位に対して投薬を実行し得るように患者の身体に
装着された投薬機構と、前記投薬管理装置からの投薬指
示に従って前記投薬機構を動作させて投薬を実行させる
投薬制御手段とを有する、ことを特徴とする投薬システ
ムである。投薬を腕からの注射で行う場合であれば、被
投薬部位は腕であるため、投薬機構は患者の腕に装着さ
れる。例えば、腕時計のような環状装着具を用いて装着
され得る。注射は一般には注射針を刺すことで行われる
が、皮膚から圧力等で薬液を浸透させる手法も可能であ
る。薬剤を投与する手法としては、注射以外に、例え
ば、薬剤噴霧、薬剤塗布等を例示できる。無線端末や投
薬制御手段は、投薬機構と一体でもよいが、別体に構成
して無線で信号を送受してもよい。無線端末が投薬機構
と別体の場合に、該無線端末として、インターネット等
のネットワークに接続可能な携帯電話を用いてもよい。According to a first aspect of the present invention, a medication management device and a medication device provided with a wireless terminal can transmit and receive data via a network, and the medication management device includes a A dosing schedule holding means having a dosing schedule, and dosing instructing means for instructing the dosing device to perform dosing to the dosing device via a network when the dosing time indicated by the dosing schedule is reached, wherein the dosing device is a part to be administered of a patient Having a medication mechanism mounted on the patient's body so as to be able to perform medication, and medication control means for performing the medication by operating the medication mechanism according to a medication instruction from the medication management device. It is a dosing system characterized by the following. When the medication is performed by injection from the arm, the medication site is the arm, and the medication mechanism is mounted on the arm of the patient. For example, it can be worn using an annular wearing device such as a watch. Injection is generally performed by piercing a syringe needle, but a technique of penetrating a drug solution from the skin by pressure or the like is also possible. As a technique for administering a drug, in addition to injection, for example, drug spraying and drug application can be exemplified. The wireless terminal and the medication control means may be integrated with the medication mechanism, or may be configured separately to transmit and receive signals wirelessly. When the wireless terminal is separate from the medication mechanism, a mobile phone connectable to a network such as the Internet may be used as the wireless terminal.
【0005】請求項2の発明は、投薬管理装置と無線端
末を備えた投薬装置とがネットワークを介してデータを
送受信可能であり、前記投薬管理装置は、前記投薬装置
の投薬スケジュールを持つ投薬計画保持手段と、前記投
薬スケジュールが指示する投薬時間になるとネットワー
クを介して前記投薬装置へ投薬を指示する投薬指示手段
と、前記投薬装置から報告された投薬完了情報を前記投
薬スケジュールに記録する投薬記録手段とを有し、前記
投薬装置は、患者の被投薬部位に対して投薬を実行し得
るように患者の身体に装着された投薬機構と、前記投薬
管理装置からの投薬指示に従って前記投薬機構を動作さ
せて投薬を実行させる投薬制御手段と、前記投薬指示に
応じた投薬の実行後にネットワークを介して前記投薬管
理装置へ投薬完了を報告する投薬報告手段とを有する、
ことを特徴とする投薬システムである。投薬が行われる
と、その旨が投薬装置から報告されて、投薬管理装置の
投薬スケジュールに記録されるため、予定されていた投
薬が滞りなく行われたか否かを投薬管理装置側で知るこ
とができる。このため、何らかの不具合が生じた場合に
は、速やかに対応策を採ることができる。According to a second aspect of the present invention, a medication management device and a medication device having a wireless terminal can transmit and receive data via a network, and the medication management device has a medication schedule having a medication schedule of the medication device. Holding means, medication instructing means for instructing the medication apparatus via the network when the medication time indicated by the medication schedule is reached, and medication record for recording medication completion information reported from the medication apparatus in the medication schedule Means, the dispensing device includes a dispensing mechanism mounted on the patient's body so as to be able to perform dispensing to a patient's dispensed site, and the dispensing mechanism in accordance with a dispensing instruction from the dispensing management device. Medication control means for operating and performing medication, and completing medication to the medication management device via a network after performing medication in accordance with the medication instruction And a dosing reporting means for reporting,
It is a medication system characterized by the above-mentioned. When the medication is administered, the fact is reported from the medication device and recorded in the medication schedule of the medication management device, so that the medication management device can know whether or not the scheduled medication has been performed without delay. it can. For this reason, when some trouble occurs, a countermeasure can be taken promptly.
【0006】請求項3の発明は、投薬管理装置と無線端
末を備えた投薬装置とがネットワークを介してデータを
送受信可能であり、前記投薬管理装置は、前記投薬装置
の投薬スケジュールを持つ投薬計画保持手段と、前記投
薬スケジュールが指示する投薬時間になるとネットワー
クを介して前記投薬装置へバイタル情報の検出を指示す
る検出指示手段と、前記投薬装置から報告されるバイタ
ル情報に基づいて当該投薬の可否を決定する投薬可否決
定手段と、前記投薬可否決定手段が投薬可と決定した場
合にネットワークを介して前記投薬装置へ投薬を指示す
る投薬指示手段と、前記投薬装置から報告された投薬完
了情報を前記投薬スケジュールに記録する投薬記録手段
とを有し、前記投薬装置は、患者の被投薬部位に対して
投薬を実行し得るように患者の身体に装着された投薬機
構と、患者のバイタル情報を検出し得るように患者の身
体に装着された検出機構と、前記投薬管理装置からの検
出指示に従って前記検出機構を動作させて検出を実行さ
せる検出制御手段と、前記検出したバイタル情報をネッ
トワークを介して前記投薬管理装置へ報告する検出報告
手段と、前記投薬管理装置からの投薬指示に従って前記
投薬機構を動作させて投薬を実行させる投薬制御手段
と、前記投薬指示に応じた投薬の実行後にネットワーク
を介して前記投薬管理装置へ投薬完了を報告する投薬報
告手段とを有する、ことを特徴とする投薬システムであ
る。バイタル情報とは生体から検出される情報であり、
例えば、脈拍、体温、最大及び最小血圧等を例示でき
る。また、微小の血液採取で検出可能な血糖値等の各種
の血液検査結果も挙げることができる。検出機構とその
装着部位は、検出対象のバイタル情報に応じて定まる。
無線端末、投薬制御手段、投薬機構は、検出機構と一体
でもよいが、別体に構成して無線で信号を送受してもよ
い。投薬可否決定手段は、例えば、バイタル情報の検出
結果から、投薬が患者の病状を悪化させると推定される
場合は、投薬否の決定を行う。According to a third aspect of the present invention, a medication management device and a medication device having a wireless terminal can transmit and receive data via a network, and the medication management device has a medication schedule having a medication schedule of the medication device. Holding means, detection instructing means for instructing the medication apparatus to detect vital information via the network when the medication time indicated by the medication schedule is reached, and whether or not the medication can be performed based on the vital information reported from the medication apparatus. Determining whether or not to administer, the medication instructing means for instructing the administration device to administer medication via a network when the administration / non-administration determination unit determines that administration is possible, and administering the medication completion information reported from the administration device. A medication recording means for recording the medication schedule, wherein the medication apparatus can perform medication to a patient's medication site. A medication mechanism mounted on the patient's body, a detection mechanism mounted on the patient's body so that vital information of the patient can be detected, and a detection mechanism operated according to a detection instruction from the medication management device for detection Control means for executing the above, a detection report means for reporting the detected vital information to the medication management device via a network, and causing the medication mechanism to operate in accordance with a medication instruction from the medication management device to perform medication. A dosing system comprising: a dosing control unit; and a dosing reporting unit that reports completion of dosing to the dosing management device via a network after performing dosing according to the dosing instruction. Vital information is information detected from a living body,
For example, pulse, body temperature, maximum and minimum blood pressure, and the like can be exemplified. In addition, various blood test results such as a blood sugar level that can be detected by minute blood sampling can also be mentioned. The detection mechanism and its mounting site are determined according to vital information to be detected.
The wireless terminal, the medication control means, and the medication mechanism may be integrated with the detection mechanism, or may be configured separately to transmit and receive signals wirelessly. The medication determination unit determines, for example, if the medication is presumed to deteriorate the patient's condition based on the detection result of the vital information.
【0007】請求項4の発明は、請求項3に於いて、前
記投薬管理装置の投薬可否決定手段は前記バイタル情報
に基づいて投薬量を調整する機能を更に有し、前記投薬
管理装置の投薬指示手段は前記投薬可否決定手段が決定
した投薬量を前記投薬装置へ指示する機能を更に有し、
前記投薬装置の投薬機構は前記検出制御手段が指示する
量の投薬動作を実行する機能を更に有する、ことを特徴
とする投薬システムである。投薬可否決定手段は、例え
ば、バイタル情報の検出結果から投薬が患者の病状を悪
化させると推定される場合には、投薬量を減らしたり若
しくは投薬否と決定する。一方、バイタル情報の検出結
果から更なる投薬が必要であると推定される場合には、
投薬量を増やすように決定する。また、投薬の時間間隔
を変更するように、換言すれば、投薬スケジュールを変
更するように決定してもよい。請求項5の発明は、請求
項3又は請求項4に於いて、前記投薬管理装置は、さら
に、電子カルテに基づいて前記投薬スケジュールを作成
する投薬計画作成手段と、前記投薬記録手段が前記投薬
スケジュールに記録した投薬完了情報を前記電子カルテ
に渡す完了情報転記手段とを有する、ことを特徴とする
投薬システムである。請求項6の発明は、請求項1〜請
求項5の何れかに於いて、前記ネットワークはインター
ネットである、ことを特徴とする投薬システムである。According to a fourth aspect of the present invention, in the third aspect, the administration determining unit of the administration device further has a function of adjusting a dosage based on the vital information. Instructing means further has a function of instructing the dosage device the dosage determined by the dosage determination unit,
The dispensing system of the dispensing device further has a function of executing a dispensing operation of an amount specified by the detection control unit. For example, when it is presumed from the detection result of the vital information that the medication deteriorates the patient's medical condition, the medication availability determination means reduces the dosage or decides whether or not to administer the medication. On the other hand, when it is estimated that further medication is necessary from the detection result of the vital information,
Decide to increase the dosage. Further, it may be determined to change the time interval of the medication, in other words, to modify the medication schedule. According to a fifth aspect of the present invention, in the third or fourth aspect, the medication management device further comprises a medication plan creating means for creating the medication schedule based on an electronic medical record, and the medication recording means. A medication information transfer means for passing medication completion information recorded in a schedule to the electronic medical record. A sixth aspect of the present invention is the drug administration system according to any one of the first to fifth aspects, wherein the network is the Internet.
【0008】請求項7の発明は、投薬スケジュールを持
つ投薬管理装置と、患者の被投薬部位に対して投薬を実
行し得るように患者の身体に装着された投薬機構と無線
端末とを備えた投薬装置とが、ネットワークを介してデ
ータを送受信可能であり、前記投薬管理装置は前記投薬
スケジュールが指示する投薬時間になるとネットワーク
を介して前記投薬装置へ投薬を指示し、前記投薬装置は
前記投薬管理装置からの投薬指示に従って前記投薬機構
を動作させて投薬を実行させる、ことを特徴とする投薬
方法である。請求項8の発明は、投薬スケジュールを持
つ投薬管理装置と、患者の被投薬部位に対して投薬を実
行し得るように患者の身体に装着された投薬機構と無線
端末とを備えた投薬装置とが、ネットワークを介してデ
ータを送受信可能であり、前記投薬管理装置は前記投薬
スケジュールが指示する投薬時間になるとネットワーク
を介して前記投薬装置へ投薬を指示し、前記投薬装置は
前記投薬管理装置からの投薬指示に従って前記投薬機構
を動作させて投薬を実行させた後にネットワークを介し
て前記投薬管理装置へ投薬完了を報告し、前記投薬管理
装置は前記投薬装置から報告された投薬完了情報を前記
投薬スケジュールに記録する、ことを特徴とする投薬方
法である。According to a seventh aspect of the present invention, there is provided a medication management apparatus having a medication schedule, a medication mechanism mounted on a patient's body so as to be able to execute medication to a medication site of the patient, and a wireless terminal. A medication device, capable of transmitting and receiving data via a network, wherein the medication management device instructs the medication device to administer the medication via the network when the medication time indicated by the medication schedule is reached, and A dosing method characterized in that the dosing mechanism is operated according to a dosing instruction from a management device to perform dosing. The invention of claim 8 provides a medication management device having a medication schedule, a medication device equipped with a medication mechanism mounted on a patient's body so as to be able to execute medication to a patient's medication site, and a wireless terminal. However, data can be transmitted and received via a network, and the medication management device instructs medication to the medication device via the network when the medication time indicated by the medication schedule is reached, and the medication device is transmitted from the medication management device. Operating the medication mechanism in accordance with the medication instruction to execute medication, and then reporting the medication completion to the medication management device via the network, and the medication management device reports the medication completion information reported from the medication device to the medication administration. A dosing method characterized by recording on a schedule.
【0009】請求項9の発明は、投薬スケジュールを持
つ投薬管理装置と、患者の被投薬部位に対して投薬を実
行し得るように患者の身体に装着された投薬機構と患者
のバイタル情報を検出し得るように患者の身体に装着さ
れた検出機構と無線端末とを備えた投薬装置とが、ネッ
トワークを介してデータを送受信可能であり、前記投薬
管理装置は前記投薬スケジュールが指示する投薬時間に
なるとネットワークを介して前記投薬装置へバイタル情
報の検出を指示し、前記投薬装置は前記投薬管理装置か
らの検出指示に従って前記検出機構を動作させて検出を
実行させた後に検出したバイタル情報をネットワークを
介して前記投薬管理装置へ報告し、前記投薬管理装置は
前記投薬装置から報告されるバイタル情報に基づいて当
該投薬の可否を決定するとともに投薬可と決定した場合
はネットワークを介して前記投薬装置へ投薬を指示し、
前記投薬装置は前記投薬管理装置からの投薬指示に従っ
て前記投薬機構を動作させて投薬を実行させた後にネッ
トワークを介して前記投薬管理装置へ投薬完了を報告
し、前記投薬管理装置は前記投薬装置から報告された投
薬完了情報を前記投薬スケジュールに記録する、ことを
特徴とする投薬方法である。According to a ninth aspect of the present invention, there is provided a medication management apparatus having a medication schedule, a medication mechanism mounted on a patient's body so as to be able to execute medication for a patient's medication site, and detecting patient's vital information. A medication device equipped with a detection mechanism and a wireless terminal attached to the patient's body so as to be able to transmit and receive data via a network, and the medication management device operates at a medication time indicated by the medication schedule. Then, instruct the detection of vital information to the medication device via a network, the medication device operates the detection mechanism according to the detection instruction from the medication management device, performs the detection, and executes the detection. Via the vital information reported from the dispensing device. If it is determined that dosing friendly as well as instructs the dosage to the dispensing device via a network,
The dosing device operates the dosing mechanism according to the dosing instruction from the dosing management device to perform the dosing, and then reports the completion of the dosing to the dosing management device via a network, and the dosing management device transmits the dosing device from the dosing device. A medication method, wherein the reported medication completion information is recorded in the medication schedule.
【0010】請求項10の発明は、投薬スケジュールを
持つ投薬管理装置と、患者の被投薬部位に対して投薬を
実行し得るように患者の身体に装着された投薬機構と患
者のバイタル情報を検出し得るように患者の身体に装着
された検出機構と無線端末とを備えた投薬装置とが、ネ
ットワークを介してデータを送受信可能であり、前記投
薬管理装置は前記投薬スケジュールが指示する投薬時間
になるとネットワークを介して前記投薬装置へバイタル
情報の検出を指示し、前記投薬装置は前記投薬管理装置
からの検出指示に従って前記検出機構を動作させて検出
を実行させた後に検出したバイタル情報をネットワーク
を介して前記投薬管理装置へ報告し、前記投薬管理装置
は前記投薬装置から報告されるバイタル情報に基づいて
当該投薬の可否と投薬可の場合の投薬量を決定するとと
もに投薬可と決定した場合はネットワークを介して前記
投薬装置へ投薬量を指示し、前記投薬装置は前記投薬管
理装置からの投薬量指示に従って前記投薬機構を動作さ
せて指示量の投薬を実行させた後にネットワークを介し
て前記投薬管理装置へ指示量の投薬完了を報告し、前記
投薬管理装置は前記投薬装置から報告された指示量の投
薬完了情報を前記投薬スケジュールに記録する、ことを
特徴とする投薬方法である。[0010] According to a tenth aspect of the present invention, a medication management device having a medication schedule, a medication mechanism mounted on a patient's body so as to be able to execute medication to a patient's medication site, and vital information of the patient are detected. A medication device equipped with a detection mechanism and a wireless terminal attached to the patient's body so as to be able to transmit and receive data via a network, and the medication management device operates at a medication time indicated by the medication schedule. Then, instruct the detection of vital information to the medication device via a network, the medication device operates the detection mechanism according to the detection instruction from the medication management device, performs the detection, and executes the detection. Reporting to the medication management device via the medication management device, based on the vital information reported from the medication device, When the dosage is determined to be medicable, and when it is determined that the medication is possible, the dosage is instructed to the medication device via a network, and the medication device controls the medication mechanism according to the dosage instruction from the medication management device. After operating and causing the prescribed amount of medication to be executed, the completion of the prescribed amount of medication is reported to the medication administration device via the network, and the medication administration device transmits the medication completion information of the prescribed amount reported from the medication device to the medication administration device. A dosing method characterized by recording in a dosing schedule.
【0011】請求項11の発明は、請求項9又は請求項
10に於いて、前記投薬スケジュールは電子カルテに基
づいて作成されたものであり、前記投薬管理装置は前記
投薬スケジュールに記録した投薬完了情報を前記電子カ
ルテに渡す、ことを特徴とする投薬方法である。請求項
12の発明は、請求項7〜請求項11の何れかに於い
て、前記ネットワークはインターネットである、ことを
特徴とする投薬方法である。According to an eleventh aspect of the present invention, in the ninth or tenth aspect, the medication schedule is created based on an electronic medical record, and the medication management device is configured to record the medication completion recorded in the medication schedule. A dosing method characterized in that information is passed to the electronic medical record. According to a twelfth aspect of the present invention, there is provided the medication method according to any one of the seventh to eleventh aspects, wherein the network is the Internet.
【0012】請求項13の発明は、インターネットに接
続可能な無線端末と、被投薬部位への投薬可能に患者の
身体に装着される投薬機構と、前記無線端末手段を介し
てインターネットから受信される投薬指示に従って前記
投薬機構を動作させて投薬を実行させる投薬制御手段
と、前記投薬の実行後にその旨を前記無線端末を介して
所定の投薬管理装置宛てにインターネットへ送出する投
薬報告手段と、を有することを特徴とする投薬装置であ
る。即ち、請求項2のシステムで用いられる投薬装置で
ある。請求項14の発明は、インターネットに接続可能
な無線端末と、被投薬部位への投薬可能に患者の身体に
装着される投薬機構と、バイタル情報の検出可能に患者
の身体に装着される検出機構と、前記無線端末手段を介
してインターネットから受信される検出指示に従って前
記検出機構を動作させて前記バイタル情報を検出させる
検出制御手段と、前記検出したバイタル情報を前記無線
端末を介して所定の投薬管理装置宛てにインターネット
へ送出する検出報告手段と、前記無線端末手段を介して
インターネットから受信される投薬指示に従って前記投
薬機構を動作させて投薬を実行させる投薬制御手段と、
前記投薬の実行後にその旨を前記無線端末を介して所定
の投薬管理装置宛てにインターネットへ送出する投薬報
告手段と、を有することを特徴とする投薬装置である。
即ち、請求項3のシステムで用いられる投薬装置であ
る。[0013] According to a thirteenth aspect of the present invention, a wireless terminal connectable to the Internet, a medication mechanism mounted on a patient's body so as to be able to administer a medication site, and a radio terminal received from the Internet via the wireless terminal means Medication control means for operating the medication mechanism in accordance with a medication instruction to execute medication, and medication report means for transmitting the effect to the predetermined medication management device via the wireless terminal to the Internet after the medication is executed, It is a dosing device characterized by having. That is, a dosing device used in the system of claim 2. The invention according to claim 14 is a wireless terminal connectable to the Internet, a medication mechanism attached to a patient's body so as to be able to administer a medication site, and a detection mechanism attached to a patient's body so that vital information can be detected. Detection control means for operating the detection mechanism in accordance with a detection instruction received from the Internet via the wireless terminal means to detect the vital information; and administering the detected vital information to the prescribed medication via the wireless terminal. Detection reporting means for sending to the Internet to the management device, medication control means for operating the medication mechanism in accordance with a medication instruction received from the Internet via the wireless terminal means to perform medication,
And a medication reporting unit for transmitting the fact to the Internet via the wireless terminal after the execution of the medication to the prescribed medication management device.
That is, a dosing device used in the system of claim 3.
【0013】[0013]
【発明の実施の形態】以下、図面を参照して本発明の実
施の形態を説明する。図1は第1と第2の実施の形態の
投薬システムのネットワーク構成図であり、投薬装置1
0のブロック図を併せて示す。図2は図1内の投薬管理
装置20を示すブロック図、図3は或る患者Aの投薬ス
ケジュールを例示する説明図である。図4と図5は第1
の実施の形態の投薬システムでの手順を示すフローチャ
ートであり、図4は投薬管理装置20での投薬管理手順
を示し、図5は或る投薬装置10での投薬手順を示す。
また、図6〜図9は第2の実施の形態の投薬システムで
の手順を示すフローチャートであり、図6と図7は投薬
管理装置20での投薬管理手順を示し、図8と図9或る
投薬装置10での投薬手順を示す。Embodiments of the present invention will be described below with reference to the drawings. FIG. 1 is a network configuration diagram of a medication system according to the first and second embodiments.
0 is also shown. FIG. 2 is a block diagram showing the medication management device 20 in FIG. 1, and FIG. 3 is an explanatory diagram illustrating a medication schedule of a certain patient A. FIG. 4 and FIG.
4 is a flowchart showing a procedure in the medication system according to the embodiment, FIG. 4 shows a medication management procedure in the medication management apparatus 20, and FIG. 5 shows a medication procedure in a certain medication apparatus 10.
FIGS. 6 to 9 are flowcharts showing procedures in the medication system according to the second embodiment. FIGS. 6 and 7 show a medication management procedure in the medication management device 20, and FIGS. 1 shows a dosing procedure using the dosing device 10.
【0014】(1)第1と第2の実施の形態に共通の構
成:図1に示すように、投薬管理装置20と、複数の投
薬装置10(1),10(2),,10(i),,とが
インターネットに接続可能であり、インターネットを介
することにより相互間でのデータ送受信が可能である。(1) Configuration common to the first and second embodiments: As shown in FIG. 1, a medication management device 20 and a plurality of medication devices 10 (1), 10 (2), 10 ( i), and can be connected to the Internet, and data can be transmitted and received between them via the Internet.
【0015】各投薬装置10は、装置の各部を制御する
制御装置12を有し、該制御装置12は、インターネッ
トからの受信データを解析する受信データ解析/インタ
ーネットへ送出するデータを設定する送信データ設定機
能12aと、投薬機構17を制御する投薬制御機能12
fと、検出機構18を制御する検出制御機能12gと
を、少なくとも有する。投薬機構17は例えば注射器で
あり、装着部材(例:腕時計のバンド様の環状装着部材
等)17aによって被注射部位に装着される。この投薬
機構17は、人手操作ではなく制御装置12の投薬制御
機能12fからの信号で動作する(=薬液を注射する)
機能を有する。バイタル情報を検出する検出機構18は
例えば体温計であり、装着部材(例:粘着テープ等)1
8aによって被検温部位に装着される。この検出機構1
8は、制御装置12の検出制御機能12gからの信号に
応じて検出を行い、検出結果を制御制御機能12gへ渡
す機能を有する。また、無線端末11はインターネット
との接続機能を受け持つ。投薬機構17とその装着部材
17a,検出機構18とその装着部材18a,制御装置
12,及び無線端末11は、一体に構成されてもよく、
別体に構成されて相互間の信号の送受を無線で行っても
よい。また、これらの中の一部が一体に構成され、残部
が別体に構成されていてもよい。例えば、無線端末11
として、インターネットに接続可能な携帯電話機を用い
ることもできる。Each dispensing device 10 has a control device 12 for controlling each part of the device. The control device 12 analyzes received data from the Internet / transmitted data for setting data to be transmitted to the Internet. Setting function 12a and medication control function 12 for controlling medication mechanism 17
f, and at least a detection control function 12g that controls the detection mechanism 18. The dosing mechanism 17 is, for example, a syringe, and is mounted on the injection site by a mounting member (eg, an annular mounting member such as a wristwatch band) 17a. The dispensing mechanism 17 is operated not by manual operation but by a signal from the dispensing control function 12f of the control device 12 (= inject the drug solution).
Has functions. The detection mechanism 18 for detecting vital information is, for example, a thermometer, and the mounting member (eg, adhesive tape or the like) 1
8a is attached to the site to be measured. This detection mechanism 1
Reference numeral 8 has a function of performing detection in accordance with a signal from the detection control function 12g of the control device 12, and passing the detection result to the control control function 12g. The wireless terminal 11 has a function of connecting to the Internet. The dosing mechanism 17 and its mounting member 17a, the detection mechanism 18 and its mounting member 18a, the control device 12, and the wireless terminal 11 may be integrally formed.
The transmission and reception of signals may be performed wirelessly by being configured separately. Moreover, some of these may be integrally formed, and the rest may be separately formed. For example, the wireless terminal 11
Alternatively, a mobile phone that can be connected to the Internet can be used.
【0016】投薬管理装置20は、図2に示すように、
投薬管理機能22b・投薬計画管理機能22c・電子カ
ルテ管理機能22d・インターネットからの受信データ
を解析する受信データ解析/インターネットへ送出する
データを設定する送信データ設定機能22a・補助記憶
装置23のデータの読み出し/書込み制御機能22eを
少なくとも有する制御装置22と、各患者の投薬スケジ
ュール23aや診療情報データベース23bを少なくと
も記憶している補助記憶装置(例:ハードディスク等)
23と、インターネットとの接続機能を受け持つ通信端
末21と、キーボードやマウス等の入力装置24と、表
示装置25と、印刷装置26とを有するコンピュータ装
置である。なお、図2では投薬管理装置20は単独の装
置として示されているが、構内LANに接続されていて
もよい。As shown in FIG. 2, the medication management device 20
Medication management function 22b, medication plan management function 22c, electronic medical record management function 22d, reception data analysis for analyzing data received from the Internet, transmission data setting function 22a for setting data to be transmitted to the Internet, and data storage in auxiliary storage device 23 A control device 22 having at least a read / write control function 22e and an auxiliary storage device (eg, a hard disk or the like) storing at least a medication schedule 23a and a medical information database 23b for each patient.
23, a communication terminal 21 having a function of connecting to the Internet, an input device 24 such as a keyboard and a mouse, a display device 25, and a printing device 26. Although the medication management device 20 is shown as a single device in FIG. 2, it may be connected to a local LAN.
【0017】電子カルテ管理機能22dは、診療情報デ
ータベース23bを管理する機能である。例えば、診療
情報入力画面を表示して、該画面から入力されたデータ
を診療情報データベース23bに記録する。或いは、所
望の患者の診療情報を診療情報データベース23bから
読み出して画面に表示したり、プリントアウトしたりす
る。また、治療計画作成画面を表示して治療計画を作成
し、該作成した治療計画を診療情報データベース23b
に記録したり、プリントアウトしたりする。電子カルテ
管理機能は公知であるため、詳細な説明は省略する。The electronic medical record management function 22d is a function for managing the medical information database 23b. For example, a medical information input screen is displayed, and data input from the screen is recorded in the medical information database 23b. Alternatively, the medical information of a desired patient is read from the medical information database 23b and displayed on a screen or printed out. Further, a treatment plan creation screen is displayed to create a treatment plan, and the created treatment plan is stored in the medical information database 23b.
And print it out. Since the electronic medical record management function is publicly known, detailed description is omitted.
【0018】投薬計画管理機能22cは、診療情報デー
タベース23bから読み出したデータに基づいて、患者
毎の投薬スケジュールを作成して、補助記憶装置23に
記憶する。投薬スケジュールは、図3に例示するよう
に、投薬の順番と投薬の予定日時刻とを有し、さらに、
バイタルデータ(バイタルデータの種別は投薬対象の薬
剤等に応じて適宜に決められる)の記録欄や、投薬結果
の記録欄を有する。図3の例では、第1回〜第7回まで
インシュリンの投薬が行われ、その中で、第6回目の投
薬がバイタルデータの判定結果に基づいて不可とされた
ために実行されなかった様子が示されている。なお、第
1の実施の形態のように、投薬に先立ってバイタルデー
タを検出し、検出結果を投薬装置20から投薬管理装置
20へ送信して、投薬管理装置20にて記録するように
構成してもよいが、第2の実施の形態のように、常時又
は定期的にバイタルデータを検出し、投薬装置10から
投薬管理装置20へ定期的に送信して、投薬管理装置に
て記録する構成でもよい。常時又は定期的にバイタルデ
ータを検出して定期的に送信して記録する第2の実施の
形態の構成では、バイタルデータの異常を早期に検出で
きるため、必要な対応を速やかに採ることができる効果
がある。The medication plan management function 22c creates a medication schedule for each patient based on the data read from the medical information database 23b and stores it in the auxiliary storage device 23. The dosing schedule has a dosing order and a scheduled dosing time as illustrated in FIG.
It has a record column for vital data (the type of vital data is appropriately determined according to the medicine to be administered, etc.) and a record column for the medication result. In the example of FIG. 3, a state in which insulin was administered from the first to seventh times, and the sixth medication was not performed because it was determined to be impossible based on the determination result of the vital data. It is shown. It should be noted that, as in the first embodiment, it is configured such that vital data is detected prior to medication, a detection result is transmitted from the medication device 20 to the medication management device 20, and recorded in the medication management device 20. Alternatively, as in the second embodiment, a configuration in which vital data is constantly or periodically detected, periodically transmitted from the medication device 10 to the medication management device 20, and recorded by the medication management device. May be. In the configuration of the second embodiment in which vital data is detected constantly or periodically and transmitted and recorded periodically, an abnormality in vital data can be detected early, so that necessary measures can be taken promptly. effective.
【0019】(2)第1の実施の形態:第1の実施の形
態では、投薬管理機能22bは投薬指示に先立ってバイ
タルデータの検出を指示し、その検出結果に応じて投薬
(所定の投薬,投薬量及び/又は投薬時間間隔を増減し
た投薬)を指示し、又は投薬否と決定する。この第1の
実施の形態の投薬管理機能22bと該機能に対応する投
薬装置10の機能を、図4と図5を参照して説明する。
投薬管理装置20は、或る患者の投薬スケジュールによ
り決められている所定の投薬日時刻になると(S01で
YES)、該投薬スケジュールにより決められている所
定のバイタルデータを検出すべき旨の指示を、該或る患
者の投薬装置10宛てに、インターネットへ送出する
(S03)。(2) First Embodiment: In the first embodiment, the medication management function 22b instructs vital data detection prior to a medication instruction, and administers medication (predetermined medication) in accordance with the detection result. , Dosing with increased or decreased dosage and / or dosing time intervals), or determined to be non-medicated. The medication management function 22b of the first embodiment and the function of the medication device 10 corresponding to the medication management function 22b will be described with reference to FIGS.
When a predetermined medication day time determined by a certain patient's medication schedule comes (YES in S01), the medication management device 20 issues an instruction to detect predetermined vital data determined by the medication schedule. Then, the data is transmitted to the Internet to the medication device 10 of the certain patient (S03).
【0020】上記の指示に応答して(S51でYE
S)、当該投薬装置10では、バイタルデータが検出さ
れ、その検出結果がインターネットを介して投薬管理装
置20へ報告される(S53)。投薬管理装置20は、
バイタルデータの検出指示後所定時間(検出に十分な所
定時間)を経過した投薬装置の有無をチェックし(S1
1)、該当する投薬装置が有る場合には(S11でYE
S)、当該投薬装置からバイタルデータの検出結果が報
告されたか否かチェックする(S13)。その結果、当
該投薬装置からバイタルデータの検出結果が報告されて
いる場合は(S13でYES)、該バイタルデータを当
該投薬装置の投薬スケジュール内の該当欄に記録すると
ともに、該検出結果に基づいて投薬の可否を決定する。
また、投薬可の場合は必要に応じて投薬量を決定する
(S15)。さらに、投薬可と決定した場合は(S17
でYES)、当該投薬装置宛ての投薬指示をインターネ
ットに送出する(S19)。この時、上記ステップS1
5の決定が投薬量の増減を含む場合は、該増減後の投薬
量も併せて送信する。一方、バイタルデータの検出指示
後、検出に十分な所定時間を経過したにもかかわらず未
だバイタルデータの検出結果を報告しない投薬装置が有
る場合は(S11でYES,且つ,S13でNO)、当
該投薬装置の投薬スケジュール内の該当欄に「投薬エラ
ー」を記録する(S21)。また、上記ステップS17
で「投薬不可」と決定した場合は(S17でNO)、当
該投薬装置の投薬スケジュール内の該当欄に「投薬不
可」を記録する(S23)。In response to the above instruction (YE in S51)
S), in the administration device 10, vital data is detected, and the detection result is reported to the administration device 20 via the Internet (S53). The medication management device 20
It is checked whether there is any medication device that has passed a predetermined time (a predetermined time sufficient for detection) after the vital data detection instruction (S1).
1) If there is a corresponding medication apparatus (YE in S11)
S), it is checked whether or not the result of detecting the vital data is reported from the administration device (S13). As a result, when the result of detection of vital data is reported from the administration device (YES in S13), the vital data is recorded in a corresponding column in the administration schedule of the administration device, and based on the detection result. Decide whether to administer the drug.
If the medication is possible, the dosage is determined as necessary (S15). Further, when it is determined that medication is possible (S17)
YES), and sends a medication instruction addressed to the medication device to the Internet (S19). At this time, the above step S1
If the determination of 5 includes an increase or decrease in the dosage, the dosage after the increase or decrease is also transmitted. On the other hand, if there is a medication device that has not yet reported the detection result of vital data even though a predetermined time sufficient for the detection has elapsed after the vital data detection instruction (YES in S11 and NO in S13), The “medication error” is recorded in a corresponding column in the medication schedule of the medication device (S21). Step S17
If it is determined that "dosing is impossible" (NO in S17), "dosing not possible" is recorded in the corresponding column in the dosing schedule of the dosing device (S23).
【0021】上記ステップS19の指示に応じて(S6
1でYES)、当該投薬装置10では、投薬が実行さ
れ、その後、投薬完了の旨がインターネットを介して投
薬管理装置20へ報告される(S63)。In response to the instruction in step S19 (S6
(YES in 1), the medication is performed in the medication device 10, and then the completion of the medication is reported to the medication management device 20 via the Internet (S63).
【0022】投薬管理装置20は、投薬指示後所定時間
(投薬に十分な所定時間)を経過した投薬装置の有無を
チェックし(S31)、該当する投薬装置が有る場合は
(S31でYES)、当該投薬装置から投薬完了の旨が
報告されたか否かチェックする(S33)。その結果、
当該投薬装置から投薬完了の旨が報告されている場合は
(S33でYES)、当該投薬装置の投薬スケジュール
内の該当欄に「投薬済み」を記録する(S35)。一
方、投薬指示後、投薬に十分な所定時間を経過したにも
かかわらず未だ投薬完了の旨を報告しない投薬装置が有
る場合は(S31でYES,且つ,S33でNO)、当
該投薬装置の投薬スケジュール内の該当欄に「投薬エラ
ー」を記録する(S37)。The medication management device 20 checks whether there is a medication device that has passed a predetermined time (predetermined time sufficient for medication) after instructing the medication (S31), and if there is a corresponding medication device (YES in S31), It is checked whether or not the completion of the administration is reported from the administration apparatus (S33). as a result,
When the administration device reports that the administration is completed (YES in S33), “medicated” is recorded in the corresponding column in the administration schedule of the administration device (S35). On the other hand, if there is a medication device that has not yet reported the completion of medication even though a predetermined time sufficient for medication has passed after the medication instruction (YES in S31 and NO in S33), the medication of the medication device The “medication error” is recorded in the corresponding column in the schedule (S37).
【0023】上記では「投薬不可」の場合や「投薬エラ
ー」の場合の対応策について言及していないが、例え
ば、投薬管理装置20のオペレータに警告出力(アラー
ム,画面上の点滅表示等)して、当該患者へ電話で問い
合わせをさせたり、必要に応じて救急車を派遣する等の
対応策を採らせてもよい。Although no countermeasures have been described above in the case of “medication not possible” or “medication error”, for example, a warning is output to the operator of the medication management device 20 (alarm, blinking display on the screen, etc.). Then, the patient may be inquired by telephone, or an ambulance may be dispatched if necessary.
【0024】また、上記では、投薬量を調整(増減)す
る際、該投薬量の増減とともに、又は第投薬量の増減と
は別個独立に、他の対応策を採るか否かについて言及し
ていないが、例えば、バイタルデータの検出結果に基づ
いて投薬の時間間隔を増減する(=投薬スケジュールを
変更する)等の対応策を採るようにしてもよい。In addition, the above mentions whether to adjust (increase or decrease) the dosage, together with the increase or decrease of the dosage, or independently of the increase or decrease of the first dosage, whether to adopt another countermeasure. However, for example, a countermeasure such as increasing or decreasing the medication time interval (= changing the medication schedule) based on the detection result of the vital data may be adopted.
【0025】また、上記では、投薬管理装置20が投薬
管理機能と電子カルテ管理とを併せ持つ場合を述べてい
るが、投薬管理装置20が電子カルテ機能を持たず、別
の電子カルテ装置から診療情報を取得して投薬スケジュ
ールを作成するように構成することも当然に可能であ
る。また、その場合に於いて、両者間のデータの送受を
インターネットを介して行うように構成することもでき
る。In the above description, the case where the medication management apparatus 20 has both the medication management function and the electronic medical chart management is described. However, the medication management apparatus 20 does not have the electronic medical chart function, and the medical information management apparatus 20 receives the medical information from another electronic medical chart apparatus. It is of course also possible to configure so as to create a medication schedule by acquiring In such a case, data transmission and reception between the two may be performed via the Internet.
【0026】(3)第2の実施の形態:第2の実施の形
態では、投薬装置10は常時又は定期的にバイタルデー
タを検出し、その検出結果を、インターネットを介して
定期的に投薬管理装置20に報告する。この報告に基づ
いて、投薬管理装置20は投薬スケジール変更の必要性
をチェックし、必要であれば投薬スケジュールを変更す
る。投薬装置10は、また、常時又は定期的に検出する
バイタルデータに異常が認められた場合は、異常の旨と
その検出結果とをインターネットを介して速やかに投薬
管理装置20に報告する。この報告に応じて、投薬管理
装置20は、緊急投薬等の処置を行い、さらに、必要に
応じて救急車の派遣等を行う。このような機能を持つ第
2の実施の形態の投薬管理機能22bと該機能に対応す
る投薬装置10の機能を、図6〜図9を参照して説明す
る。(3) Second embodiment: In the second embodiment, the administration device 10 constantly or periodically detects vital data, and periodically transmits the result of administration to the medication management via the Internet. Report to device 20. Based on this report, the medication management device 20 checks the necessity of changing the medication schedule, and changes the medication schedule if necessary. When an abnormality is found in the vital data that is constantly or periodically detected, the medication device 10 immediately reports the abnormality and the detection result to the medication management device 20 via the Internet. In response to this report, the medication management device 20 performs a treatment such as an emergency medication, and further dispatches an ambulance if necessary. The medication management function 22b of the second embodiment having such a function and the function of the medication device 10 corresponding to the function will be described with reference to FIGS.
【0027】不図示の時計を有する投薬装置10は、当
該投薬装置に関して予め決められている検出時刻になる
と(S151出YES)、バイタルデータを検出し(S
153)、該検出したバイタルデータをチェックする
(S155)。その結果、異常が有る場合は(S157
でYES)、異常を検出した旨とバイタルデータとをイ
ンターネットを介して投薬管理装置10に報告する(S
161)。異常とは、例えば、バイタルデータの検出値
が所定の許容範囲を外れた場合である。The dispensing device 10 having a clock (not shown) detects vital data when a predetermined detection time is reached for the dispensing device (YES in S151) (S151).
153), the detected vital data is checked (S155). As a result, when there is an abnormality (S157)
YES), and reports that the abnormality has been detected and vital data to the medication management apparatus 10 via the Internet (S
161). The abnormality is, for example, a case where the detected value of the vital data is out of a predetermined allowable range.
【0028】一方、上記ステップS155のチェックで
異常が無かった場合は(S155でNO)、該バイタル
データをメモリ上に保持し(S159)、当該投薬装置
に関して予め決められている所定の報告時刻になると
(S171でYES)、上記の如くメモリ上に保持した
バイタルデータを、インターネットを介して投薬管理装
置20に報告する(S159)。On the other hand, if there is no abnormality in the check in step S155 (NO in S155), the vital data is stored in the memory (S159), and the vital data is stored at a predetermined reporting time determined in advance for the medication apparatus. When this happens (YES in S171), the vital data held in the memory as described above is reported to the medication management device 20 via the Internet (S159).
【0029】投薬管理装置20は、異常を検出した旨が
投薬装置から報告されると(S101でYES)、異常
対応の処理を行う(S103)。ここでは、当該異常を
報告した投薬装置の無線端末(例:携帯電話機)を呼び
出して状況を確認し、該状況に応じた処理を行う。例え
ば、緊急の投薬が必要であれば、緊急の投薬を当該投薬
装置に対して指示する。また、状況が緊急の投薬程度で
は不十分な場合や、上記の呼び出しに対する応答が無い
場合等、重大な状況の場合には、救急車の派遣等を手配
する。また、異常時処理フラグを1にする(S10
3)。When the administration device 20 reports that the abnormality has been detected from the administration device (YES in S101), the administration device 20 performs a process for dealing with the abnormality (S103). Here, a wireless terminal (eg, a mobile phone) of the medication device that has reported the abnormality is called to check the situation, and a process according to the situation is performed. For example, if urgent dosing is required, urgent dosing is instructed to the dosing device. In the case of a serious situation, such as when the situation is not sufficient for an emergency medication or when there is no response to the above call, dispatch of an ambulance or the like is arranged. In addition, the abnormality processing flag is set to 1 (S10
3).
【0030】投薬管理装置20から緊急の投薬等の処置
(異常時処置)を指示された投薬装置は、該指示に応答
して(S163でYES)、指示された処置を実行する
(S165)。また、該処置から所定時間(実行した緊
急処置の効果の発現に十分な所定時間)が経過すると
(S181でYES)、バイタル情報を検出して(S1
83)、該バイタル情報をチェック(評価)する(S1
85)。その結果、異常が認められなくなった場合は
(S187でNO)、異常から回復した旨をインターネ
ットを介して投薬管理装置20に報告する(S18
9)。The dosing device instructed by the medication management device 20 to perform a treatment such as urgent medication (abnormal treatment) responds to the instruction (YES in S163) and executes the instructed treatment (S165). In addition, when a predetermined time (a predetermined time sufficient for the effect of the executed emergency treatment to appear) has elapsed from the treatment (YES in S181), vital information is detected (S1).
83), the vital information is checked (evaluated) (S1)
85). As a result, when the abnormality is no longer recognized (NO in S187), the fact that the abnormality has been recovered is reported to the medication management device 20 via the Internet (S18).
9).
【0031】なお、緊急処置を実施したにもかかわらず
上記ステップS187で依然として異常であると判定さ
れた場合や(S187でYES)、今回の異常の報告後
所定時間が経過したにもかかわらず投薬管理装置20か
ら緊急処置の指示等が受信されなかった場合は(S16
7でNO)、異常時終了処理を行い(S169)、当該
投薬装置での処理を終了する。If it is determined in step S187 that the abnormality is still abnormal despite the execution of the emergency treatment (YES in step S187), or even if a predetermined time has elapsed since the current abnormality was reported, If no emergency treatment instruction or the like is received from the management device 20 (S16
(NO in 7), an abnormal-time termination process is performed (S169), and the process in the administration device is terminated.
【0032】投薬管理装置20では、繰り返して実行さ
れるループ中に於いて、今回の異常時の処理が完了して
いない場合は(S110でYES)、ステップS111
〜S119の処理(異常時の処理を終結するための処
理)を経て、ステップS121以降の処理(投薬管理装
置20の通常時の処理)に進む。また、今回の異常時の
処理が完了した後は(S110でNO)、直ちにステッ
プS121以降の処理に進む。In the medication management apparatus 20, if the current abnormal processing is not completed in the loop repeatedly executed (YES in S110), step S111.
After the processing of steps S119 to S119 (processing for ending the processing at the time of abnormality), the processing proceeds to the processing of step S121 and thereafter (the processing of the medication management apparatus 20 in the normal state). After the process at the time of this abnormality is completed (NO in S110), the process immediately proceeds to the processes in step S121 and thereafter.
【0033】まず、ステップS111〜S119の処理
を説明する。ステップS103で緊急投薬等の緊急処置
を指示した場合は(S111でYES)、該緊急処置の
効果の発現に十分な所定時間の経過を待って(S113
でYES)、異常から回復した旨の報告が当該投薬装置
から受信されたか否かチェックする(S115)。その
結果、異常から回復した旨が受信された場合は(S11
5でYES)、異常時処理フラグを0にする(S11
9)。これにより、当該投薬装置の異常時の処理は終結
する。つまり、次ループからは、ステップS111〜S
119の処理は実行されなくなる。First, the processing of steps S111 to S119 will be described. If an emergency treatment such as an emergency medication is instructed in step S103 (YES in S111), a predetermined time sufficient for the effect of the emergency treatment to elapse is waited (S113).
YES), it is checked whether or not a report indicating that recovery from the abnormality has been received from the medication apparatus (S115). As a result, when it is received that recovery from the abnormality has been received (S11
If the answer is 5 (YES at S5), the abnormal-state processing flag is set to 0 (S11).
9). As a result, the process at the time of abnormality of the administration device ends. That is, from the next loop, steps S111 to S111
Step 119 is not executed.
【0034】一方、上記ステップS115で、異常から
回復した旨が受信されなかったと判定された場合は(S
115でNO)、当該投薬装置の管理状態を「異常時終
了状態」に設定して(S117)、異常時処理フラグを
0にする(S119)。これにより、次ループからはス
テップS111〜S119の処理は実行されなくなると
ともに、当該投薬装置が「異常時終了」した旨が、当該
投薬装置の投薬スケジュールに記録される。また、その
旨が電子カルテに転記される。On the other hand, when it is determined in step S115 that the recovery from the abnormality has not been received (S115).
115 (NO at 115), the management state of the dispensing device is set to “abnormal termination state” (S117), and the abnormal processing flag is set to 0 (S119). As a result, the processes in steps S111 to S119 are not performed from the next loop, and the fact that the medication device has been "terminated abnormally" is recorded in the medication schedule of the medication device. In addition, the fact is transferred to the electronic medical record.
【0035】なお、前記ステップS103での処理が、
救急車の派遣等を指示する処理であった場合は(S11
9でYES)、直ちに当該投薬装置の管理状態を「異常
時終了状態」にして(S117)、異常時処理フラグを
0にする(S119)。Note that the processing in step S103 is as follows:
If the processing is an instruction to dispatch an ambulance or the like (S11
(YES in 9), immediately set the administration state of the administration apparatus to the “abnormal termination state” (S117), and set the abnormal processing flag to 0 (S119).
【0036】ステップS121〜S129は、投薬装置
毎に予め決められている報告時刻にインターネットから
受信されるバイタル情報、つまり、非異常時(定常時)
の情報として受信されるバイタル情報の処理である。Steps S121 to S129 are for vital information received from the Internet at a report time predetermined for each medication device, that is, for non-abnormal (normal) times.
This is the processing of the vital information received as the information.
【0037】何れかの投薬装置からバイタル情報が受信
されると(S121でYES)、該バイタル情報を、当
該投薬装置の投薬スケジュールの該当欄に記録する(S
123)。また、受信したバイタル情報に基づいて、投
薬スケジュールの変更の必要性をチェックする(S12
5)。例えば、投薬の時間間隔の増減の必要性や、投薬
量の増減の必要性をチェックする。その結果、変更が必
要な場合は(S127でYES)、該必要性に適合する
ように、当該投薬装置の投薬スケジュールを変更する
(S129)。When vital information is received from any of the administration devices (YES in S121), the vital information is recorded in a corresponding column of the administration schedule of the administration device (S121).
123). Further, the necessity of changing the medication schedule is checked based on the received vital information (S12).
5). For example, the necessity of increasing or decreasing the time interval of administration or the necessity of increasing or decreasing the dosage is checked. As a result, if a change is necessary (YES in S127), the dosing schedule of the dosing device is changed to conform to the need (S129).
【0038】ステップS131〜S147は、各投薬装
置が各々持つ投薬スケジュールに従って、各投薬装置に
投薬を実行させるための処理である。何れかの投薬装置
の投薬スケジュールが持つ投薬時刻になると(S131
でYES)、当該投薬装置へ投薬を実施すべき旨を指示
する(S133)。Steps S131 to S147 are processes for causing each dispensing device to execute the dispensing according to the dispensing schedule of each dispensing device. When the medication time of the medication schedule of any medication device comes (S131)
YES), and instructs the administration device to administer the administration (S133).
【0039】この指示に応答して(S175でYE
S)、当該投薬装置は投薬を実行し(S177)、指示
された投薬が完了すると、その旨を、インターネットを
介して投薬管理装置20に報告する(S177)。In response to this instruction (YE in S175)
S), the medication device executes the medication (S177), and when the instructed medication is completed, reports the fact to the medication management device 20 via the Internet (S177).
【0040】投薬管理装置20は、或る投薬装置への投
薬の指示後、該投薬の実施とその投薬完了の報告に十分
な所定時間が経過すると(S141でYES)、当該投
薬装置からの「投薬完了」の報告を受信したか否かチェ
ックする(S143)。その結果、受信した場合は(S
143でYES)、当該投薬装置の投薬スケジュールの
該当欄に「投薬済み」を記録する。一方、上記の十分な
時間が経過したにもかかわらず未だ当該投薬装置から
「投薬完了」の報告を受信していない場合は(S143
でNO)、当該投薬装置の投薬スケジュールの該当欄に
「投薬エラー」を記録する(S147)。After a prescribed time period sufficient for the administration of the medication and the report of the completion of the medication has elapsed (YES in S141), the medication management device 20 receives the instruction from the medication device after the instruction of the medication to the medication device. It is checked whether a report of “medication completed” has been received (S143). As a result, if received (S
“YES” at 143), “medicated” is recorded in the corresponding column of the medication schedule of the medication apparatus. On the other hand, in the case where a report of “medication completion” has not yet been received from the administration device even though the sufficient time has elapsed (S143)
NO), “medication error” is recorded in the corresponding column of the medication schedule of the administration device (S147).
【0041】上記の構成では、投薬装置側でバイタル情
報の異常の有無をチェックしているが、このような構成
に代えて、投薬管理装置20側でバイタル情報の異常の
有無をチェックするようにしてもよい。In the above-described configuration, the presence or absence of the vital information is checked on the medication device side. Instead, the presence or absence of the vital information is checked on the medication management device 20 side. You may.
【0042】[0042]
【発明の効果】請求項1の発明では、投薬管理装置は投
薬装置の投薬スケジュールを持ち、投薬スケジュールが
指示する投薬時間になるとネットワークを介して投薬装
置へ投薬を指示する。一方、投薬装置は、患者の被投薬
部位に対して投薬を実行し得るように患者の身体に装着
された投薬機構を有し、投薬管理装置からの投薬指示に
従って投薬機構を動作させて投薬を実行させる。このた
め、慢性疾患のように長期間に渡って患者が自分で薬剤
を投与する必要がある場合でも、確実に薬剤を投与する
ことができる。請求項2の発明では、請求項1の構成に
於いて、投薬装置は投薬完了後にその旨を投薬管理装置
へ報告し、投薬管理装置はその報告を投薬スケジュール
に記録するため、請求項1の効果に加えて、投薬管理装
置側で投薬の状況を把握できる効果がある。即ち、何ら
かの不具合が生じた場合には、速やかに対応策を採るこ
とができる効果がある。請求項3の発明では、請求項2
の構成に於いて、投薬管理装置は、投薬の指示に先立っ
てバイタル情報の検出を指示し、その結果に基づいて投
薬の可否を決定する。また、投薬装置は、バイタル情報
の検出と報告を行う。このため、請求項2の効果に加え
て、投薬前にその適否を知ることができ、投薬を行わな
い方が良いと推定される場合には投薬をキャンセルでき
る効果がある。According to the first aspect of the present invention, the medication management device has a medication schedule for the medication device, and when the medication schedule reaches the prescribed medication time, instructs the medication device to administer the medication via the network. On the other hand, the dispensing device has a dispensing mechanism attached to the patient's body so that the dispensing can be performed on the patient's dispensed site, and operates the dispensing mechanism in accordance with a dispensing instruction from the dispensing management device to perform dispensing. Let it run. For this reason, even when a patient needs to administer a medicine for a long period of time, such as a chronic disease, the medicine can be reliably administered. According to the second aspect of the present invention, in the configuration of the first aspect, the administration apparatus reports the completion to the administration apparatus after the completion of administration, and the administration apparatus records the report in the administration schedule. In addition to the effect, there is an effect that the medication management device side can grasp the medication situation. In other words, there is an effect that when any trouble occurs, a countermeasure can be taken promptly. In the invention of claim 3, claim 2
In the above configuration, the medication management device instructs detection of vital information prior to the medication instruction, and determines whether or not to administer the medication based on the result. The dosing device also detects and reports vital information. For this reason, in addition to the effect of claim 2, there is an effect that it is possible to know whether or not the administration is performed before the administration, and to cancel the administration if it is estimated that it is better not to administer the administration.
【0043】請求項4の発明では、請求項3の構成に於
いて、投薬管理装置は、バイタル情報の検出結果に基づ
いて投薬の可否のみならず投薬量を決定できるため、請
求項3の効果に加えて、投薬量を適正に調整できる効果
がある。請求項5の発明では、請求項3又は請求項4の
構成の効果に加えて、電子カルテに基づいて投薬スケジ
ュールを作成でき、また、投薬結果(投薬完了/投薬不
可/投薬エラー)を電子カルテに記録できる効果があ
る。請求項6の発明では、請求項1〜請求項5の何れか
の構成に於いて、前記ネットワークがインターネットで
あるため、地域的な制約を離れて、上記の各効果を達成
できる効果がある。According to the fourth aspect of the present invention, in the configuration of the third aspect, the medication management device can determine not only the availability of the medication but also the dosage based on the detection result of the vital information. In addition to the above, there is an effect that the dosage can be appropriately adjusted. According to the fifth aspect of the invention, in addition to the effects of the third or fourth aspect, a medication schedule can be created based on the electronic medical record, and a medication result (medication completion / non-administration of medication / medication error) can be displayed on the electronic medical record. There is an effect that can be recorded. According to the sixth aspect of the present invention, in any one of the first to fifth aspects, since the network is the Internet, there is an effect that each of the above-mentioned effects can be achieved without departing from regional restrictions.
【0044】請求項7〜請求項12では、それぞれ、請
求項1〜請求項6のシステムで実行され得る方法を提供
できる効果がある。請求項13では請求項2で用いられ
る投薬装置を提供できる効果があり、請求項14では請
求項3で用いられる投薬装置を提供できる効果がある。According to the seventh to twelfth aspects, there is an effect that a method which can be executed by the system according to the first to sixth aspects can be provided. Claim 13 has the effect of providing the dosing device used in claim 2, and claim 14 has the effect of providing the dosing device used in claim 3.
【図1】第1及び第2の実施の形態の投薬システムのネ
ットワーク構成図。投薬装置のブロック図を併せて示
す。FIG. 1 is a network configuration diagram of a medication system according to first and second embodiments. The block diagram of the dispensing device is also shown.
【図2】図1内の投薬管理装置20を示すブロック図。FIG. 2 is a block diagram showing a medication management device 20 in FIG.
【図3】或る患者の投薬スケジュールを例示する説明
図。FIG. 3 is an explanatory diagram illustrating a medication schedule of a certain patient.
【図4】第1の実施の形態のシステムで投薬管理装置2
0が実行する投薬管理手順を示すフローチャート。FIG. 4 shows a medication management device 2 in the system according to the first embodiment.
0 is a flow chart showing a medication management procedure executed by the user.
【図5】第1の実施の形態のシステムで投薬装置10が
実行する投薬手順を示すフローチャート。FIG. 5 is a flowchart illustrating a medication procedure executed by the medication device 10 in the system according to the first embodiment.
【図6】第2の実施の形態のシステムで投薬管理装置2
0が実行する投薬管理手順を示すフローチャートの一
部。FIG. 6 shows a medication management device 2 in the system according to the second embodiment.
0 is a part of a flowchart showing a medication management procedure to be executed.
【図7】第2の実施の形態のシステムで投薬管理装置2
0が実行する投薬管理手順を示すフローチャートの残
部。FIG. 7 shows a medication management device 2 in the system according to the second embodiment.
0 is the remainder of the flowchart showing the medication management procedure executed.
【図8】第2の実施の形態のシステムで投薬装置10が
実行する投薬手順を示すフローチャートの一部。FIG. 8 is a part of a flowchart showing a medication procedure executed by the medication device 10 in the system according to the second embodiment.
【図9】第2の実施の形態のシステムで投薬装置10が
実行する投薬手順を示すフローチャートの残部。FIG. 9 is the remaining part of the flowchart showing the medication procedure executed by the medication device 10 in the system according to the second embodiment.
10 投薬装置 20 投薬管理装置 10 medication device 20 medication management device
───────────────────────────────────────────────────── フロントページの続き (72)発明者 内田 昭 大阪府守口市京阪本通2丁目5番5号 三 洋電機株式会社内 (72)発明者 栗山 博之 大阪府守口市京阪本通2丁目5番5号 三 洋電機株式会社内 Fターム(参考) 4C066 AA09 BB01 BB10 CC01 DD11 HH30 LL12 LL30 QQ21 QQ23 QQ61 QQ62 QQ64 QQ65 QQ82 QQ84 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Akira Uchida 2-5-5 Keihanhondori, Moriguchi-shi, Osaka Sanyo Electric Co., Ltd. (72) Hiroyuki Kuriyama 2-5-5 Keihanhondori, Moriguchi-shi, Osaka No. 5 Sanyo Electric Co., Ltd. F term (reference) 4C066 AA09 BB01 BB10 CC01 DD11 HH30 LL12 LL30 QQ21 QQ23 QQ61 QQ62 QQ64 QQ65 QQ82 QQ84
Claims (14)
装置とが、ネットワークを介してデータを送受信可能で
あり、 前記投薬管理装置は、前記投薬装置の投薬スケジュール
を持つ投薬計画保持手段と、前記投薬スケジュールが指
示する投薬時間になるとネットワークを介して前記投薬
装置へ投薬を指示する投薬指示手段と、を有し、 前記投薬装置は、患者の被投薬部位に対して投薬を実行
し得るように患者の身体に装着された投薬機構と、前記
投薬管理装置からの投薬指示に従って前記投薬機構を動
作させて投薬を実行させる投薬制御手段と、を有する、 ことを特徴とする投薬システム。1. A medication management device and a medication device equipped with a wireless terminal can transmit and receive data via a network, wherein the medication management device has a medication plan holding means having a medication schedule of the medication device. And a medication instructing unit for instructing the medication device to administer medication via a network when the medication schedule indicates the prescribed medication time, wherein the medication device may execute medication to a patient's medication site. A dosing mechanism mounted on the patient's body as described above, and a dosing control means for operating the dosing mechanism in accordance with a dosing instruction from the dosing management device to execute the dosing.
装置とが、ネットワークを介してデータを送受信可能で
あり、 前記投薬管理装置は、前記投薬装置の投薬スケジュール
を持つ投薬計画保持手段と、前記投薬スケジュールが指
示する投薬時間になるとネットワークを介して前記投薬
装置へ投薬を指示する投薬指示手段と、前記投薬装置か
ら報告された投薬完了情報を前記投薬スケジュールに記
録する投薬記録手段と、を有し、 前記投薬装置は、患者の被投薬部位に対して投薬を実行
し得るように患者の身体に装着された投薬機構と、前記
投薬管理装置からの投薬指示に従って前記投薬機構を動
作させて投薬を実行させる投薬制御手段と、前記投薬指
示に応じた投薬の実行後にネットワークを介して前記投
薬管理装置へ投薬完了を報告する投薬報告手段と、を有
する、 ことを特徴とする投薬システム。2. A medication management device and a medication device having a wireless terminal can transmit and receive data via a network, wherein the medication management device has a medication plan holding means having a medication schedule of the medication device. A medication instructing unit that instructs the medication device via the network when a medication time indicated by the medication schedule is instructed, a medication recording unit that records medication completion information reported from the medication device in the medication schedule, The dispensing device has a dispensing mechanism attached to the patient's body so as to be able to perform dispensing on a patient's dispensed site, and operates the dispensing mechanism according to a dispensing instruction from the dispensing management device. A medication control means for performing medication in accordance with the medication instruction, and reporting the completion of medication to the medication management device via a network after performing the medication in accordance with the medication instruction. Dosing system characterized by having a drug reporting means.
装置とが、ネットワークを介してデータを送受信可能で
あり、 前記投薬管理装置は、前記投薬装置の投薬スケジュール
を持つ投薬計画保持手段と、前記投薬スケジュールが指
示する投薬時間になるとネットワークを介して前記投薬
装置へバイタル情報の検出を指示する検出指示手段と、
前記投薬装置から報告されるバイタル情報に基づいて当
該投薬の可否を決定する投薬可否決定手段と、前記投薬
可否決定手段が投薬可と決定した場合にネットワークを
介して前記投薬装置へ投薬を指示する投薬指示手段と、
前記投薬装置から報告された投薬完了情報を前記投薬ス
ケジュールに記録する投薬記録手段と、を有し、 前記投薬装置は、患者の被投薬部位に対して投薬を実行
し得るように患者の身体に装着された投薬機構と、患者
のバイタル情報を検出し得るように患者の身体に装着さ
れた検出機構と、前記投薬管理装置からの検出指示に従
って前記検出機構を動作させて検出を実行させる検出制
御手段と、前記検出したバイタル情報をネットワークを
介して前記投薬管理装置へ報告する検出報告手段と、前
記投薬管理装置からの投薬指示に従って前記投薬機構を
動作させて投薬を実行させる投薬制御手段と、前記投薬
指示に応じた投薬の実行後にネットワークを介して前記
投薬管理装置へ投薬完了を報告する投薬報告手段と、を
有する、 ことを特徴とする投薬システム。3. A medication management device and a medication device having a wireless terminal can transmit and receive data via a network, wherein the medication management device has a medication plan holding means having a medication schedule of the medication device. Detection instruction means for instructing the administration device to detect vital information via a network when the administration time indicated by the administration schedule is reached,
Medication decision means for deciding whether or not to administer the medication based on vital information reported from the medication apparatus, and instructing medication to the medication apparatus via a network when the medication decision means decides to permit medication. Medication instruction means;
And a medication recording means for recording medication completion information reported from the medication device in the medication schedule, wherein the medication device is applied to a patient's body so as to be able to administer medication to a patient's medication site. A mounted medication mechanism, a detection mechanism mounted on the patient's body so that vital information of the patient can be detected, and a detection control for performing the detection by operating the detection mechanism in accordance with a detection instruction from the medication management device Means, detection report means for reporting the detected vital information to the medication management device via a network, medication control means for operating the medication mechanism according to a medication instruction from the medication management device to execute medication, And a medication reporting unit that reports the completion of medication to the medication management device via a network after performing medication in accordance with the medication instruction. Dispensing system that.
情報に基づいて投薬量を調整する機能を更に有し、 前記投薬管理装置の投薬指示手段は、前記投薬可否決定
手段が決定した投薬量を前記投薬装置へ指示する機能を
更に有し、 前記投薬装置の投薬機構は、前記検出制御手段が指示す
る量の投薬動作を実行する機能を更に有する、 ことを特徴とする投薬システム。4. The medication management device according to claim 3, wherein the medication availability determination means of the medication management device further has a function of adjusting a dosage based on the vital information. The dispensing mechanism of the dispensing device further has a function of executing a dispensing operation of the amount instructed by the detection control means, further comprising a function of instructing the dispensing device of the dosage determined by the dispensation determining unit. A dosing system characterized in that:
記投薬スケジュールを作成する投薬計画作成手段と、前
記投薬記録手段が前記投薬スケジュールに記録した投薬
完了情報を前記電子カルテに渡す完了情報転記手段と、
を有する、 ことを特徴とする投薬システム。5. The medication management device according to claim 3, wherein the medication management device further comprises: a medication plan creating means for creating the medication schedule based on an electronic medical record; Completion information transfer means for passing the recorded medication completion information to the electronic medical record,
A dosing system, comprising:
と、患者の被投薬部位に対して投薬を実行し得るように
患者の身体に装着された投薬機構と無線端末とを備えた
投薬装置とが、ネットワークを介してデータを送受信可
能であり、 前記投薬管理装置は、前記投薬スケジュールが指示する
投薬時間になるとネットワークを介して前記投薬装置へ
投薬を指示し、 前記投薬装置は、前記投薬管理装置からの投薬指示に従
って前記投薬機構を動作させて投薬を実行させる、 ことを特徴とする投薬方法。7. A medication management device having a medication schedule, a medication device having a medication mechanism mounted on a patient's body and a wireless terminal so as to be able to perform medication on a medication site of the patient, Data can be transmitted and received via a network, wherein the medication management device instructs the medication device via the network when the medication time indicated by the medication schedule is instructed, and wherein the medication device is from the medication management device. A dosing method by operating the dosing mechanism in accordance with the dosing instruction of the above.
と、患者の被投薬部位に対して投薬を実行し得るように
患者の身体に装着された投薬機構と無線端末とを備えた
投薬装置とが、ネットワークを介してデータを送受信可
能であり、 前記投薬管理装置は、前記投薬スケジュールが指示する
投薬時間になるとネットワークを介して前記投薬装置へ
投薬を指示し、 前記投薬装置は、前記投薬管理装置からの投薬指示に従
って前記投薬機構を動作させて投薬を実行させた後、ネ
ットワークを介して前記投薬管理装置へ投薬完了を報告
し、 前記投薬管理装置は、前記投薬装置から報告された投薬
完了情報を前記投薬スケジュールに記録する、 ことを特徴とする投薬方法。8. A medication management device having a medication schedule, a medication device having a medication mechanism mounted on a patient's body and a wireless terminal so as to be able to execute medication to a medication site of the patient, Data can be transmitted and received via a network, wherein the medication management device instructs the medication device via the network when the medication time indicated by the medication schedule is instructed, and wherein the medication device is from the medication management device. After the medication mechanism is operated according to the medication instruction and the medication is executed, the medication completion is reported to the medication management device via a network, and the medication management device transmits the medication completion information reported from the medication device. Recording in the dosing schedule.
と、患者の被投薬部位に対して投薬を実行し得るように
患者の身体に装着された投薬機構と患者のバイタル情報
を検出し得るように患者の身体に装着された検出機構と
無線端末とを備えた投薬装置とが、ネットワークを介し
てデータを送受信可能であり、 前記投薬管理装置は、前記投薬スケジュールが指示する
投薬時間になるとネットワークを介して前記投薬装置へ
バイタル情報の検出を指示し、 前記投薬装置は、前記投薬管理装置からの検出指示に従
って前記検出機構を動作させて検出を実行させた後、検
出したバイタル情報をネットワークを介して前記投薬管
理装置へ報告し、 前記投薬管理装置は、前記投薬装置から報告されるバイ
タル情報に基づいて当該投薬の可否を決定するとともに
投薬可と決定した場合はネットワークを介して前記投薬
装置へ投薬を指示し、 前記投薬装置は、前記投薬管理装置からの投薬指示に従
って前記投薬機構を動作させて投薬を実行させた後、ネ
ットワークを介して前記投薬管理装置へ投薬完了を報告
し、 前記投薬管理装置は、前記投薬装置から報告された投薬
完了情報を前記投薬スケジュールに記録する、 ことを特徴とする投薬方法。9. A medication management device having a medication schedule, a medication mechanism mounted on a patient's body so that medication can be performed on a patient's medication site, and a patient's vital information so that patient's vital information can be detected. A medication device equipped with a detection mechanism and a wireless terminal attached to the body of the body can transmit and receive data via a network, and the medication management device communicates via the network when the medication time indicated by the medication schedule comes. And instruct the administration device to detect vital information.The administration device operates the detection mechanism in accordance with the detection instruction from the administration device to execute the detection, and then transmits the detected vital information via a network. Reporting to the medication management device, wherein the medication management device determines whether or not to administer the medication based on vital information reported from the medication device. If it is determined that medication is possible, the medication is instructed to the medication device via a network, and the medication device operates the medication mechanism according to the medication instruction from the medication management device to execute medication, A medication completion report to the medication management device via a network, wherein the medication management device records medication completion information reported from the medication device in the medication schedule.
と、患者の被投薬部位に対して投薬を実行し得るように
患者の身体に装着された投薬機構と患者のバイタル情報
を検出し得るように患者の身体に装着された検出機構と
無線端末とを備えた投薬装置とが、ネットワークを介し
てデータを送受信可能であり、 前記投薬管理装置は、前記投薬スケジュールが指示する
投薬時間になるとネットワークを介して前記投薬装置へ
バイタル情報の検出を指示し、 前記投薬装置は、前記投薬管理装置からの検出指示に従
って前記検出機構を動作させて検出を実行させた後、検
出したバイタル情報をネットワークを介して前記投薬管
理装置へ報告し、 前記投薬管理装置は、前記投薬装置から報告されるバイ
タル情報に基づいて当該投薬の可否と投薬可の場合の投
薬量を決定するとともに投薬可と決定した場合はネット
ワークを介して前記投薬装置へ投薬量を指示し、 前記投薬装置は、前記投薬管理装置からの投薬量指示に
従って前記投薬機構を動作させて指示量の投薬を実行さ
せた後、ネットワークを介して前記投薬管理装置へ指示
量の投薬完了を報告し、 前記投薬管理装置は、前記投薬装置から報告された指示
量の投薬完了情報を前記投薬スケジュールに記録する、
ことを特徴とする投薬方法。10. A medication management device having a medication schedule, a medication mechanism mounted on a patient's body so that medication can be performed on a patient's medication site, and a patient's vital information so that patient's vital information can be detected. A medication device equipped with a detection mechanism and a wireless terminal attached to the body of the body can transmit and receive data via a network, and the medication management device communicates via the network when the medication time indicated by the medication schedule comes. And instruct the administration device to detect vital information.The administration device operates the detection mechanism in accordance with the detection instruction from the administration device to execute the detection, and then transmits the detected vital information via a network. Reporting to the medication management device, wherein the medication management device determines whether or not the medication can be performed based on the vital information reported from the medication device; Determining the combined dosage and instructing the dosage device via the network when the dosage is determined to be available, the dosage device operating the dosage mechanism according to the dosage instruction from the dosage management device. After performing the prescribed amount of medication, the completion of the prescribed amount of medication is reported to the medication management device via a network, and the medication management device transmits the prescribed amount of medication completion information reported from the medication device to the medication administration device. Record on the dosing schedule,
A dosing method characterized in that:
たものであり、前記投薬管理装置は前記投薬スケジュー
ルに記録した投薬完了情報を前記電子カルテに渡す、こ
とを特徴とする投薬方法。11. The medication schedule according to claim 9, wherein the medication schedule is created based on an electronic medical record, and the medication management device stores medication completion information recorded in the medication schedule in the electronic medical record. A dosing method.
て、 前記ネットワークはインターネットである、 ことを特徴とする投薬方法。12. The medication method according to claim 7, wherein the network is the Internet.
と、 被投薬部位への投薬可能に患者の身体に装着される投薬
機構と、 前記無線端末手段を介してインターネットから受信され
る投薬指示に従って前記投薬機構を動作させて投薬を実
行させる投薬制御手段と、 前記投薬の実行後にその旨を前記無線端末を介して所定
の投薬管理装置宛てにインターネットへ送出する投薬報
告手段と、 を有することを特徴とする投薬装置。13. A wireless terminal connectable to the Internet, a medication mechanism attached to a patient's body so as to be able to administer a medication site, and the medication according to a medication instruction received from the Internet via the wireless terminal means. Medication control means for operating a mechanism to execute medication, and medication report means for transmitting the effect to the predetermined medication management device via the wireless terminal to the Internet after the administration of the medication. Dosing device.
と、 被投薬部位への投薬可能に患者の身体に装着される投薬
機構と、 バイタル情報の検出可能に患者の身体に装着される検出
機構と、 前記無線端末手段を介してインターネットから受信され
る検出指示に従って前記検出機構を動作させて前記バイ
タル情報を検出させる検出制御手段と、 前記検出したバイタル情報を前記無線端末を介して所定
の投薬管理装置宛てにインターネットへ送出する検出報
告手段と、 前記無線端末手段を介してインターネットから受信され
る投薬指示に従って前記投薬機構を動作させて投薬を実
行させる投薬制御手段と、 前記投薬の実行後にその旨を前記無線端末を介して所定
の投薬管理装置宛てにインターネットへ送出する投薬報
告手段と、 を有することを特徴とする投薬装置。14. A wireless terminal connectable to the Internet, a medication mechanism attached to a patient's body so as to be able to administer a medication site, a detection mechanism attached to a patient's body so that vital information can be detected, Detection control means for operating the detection mechanism in accordance with a detection instruction received from the Internet via the wireless terminal means to detect the vital information; and a prescribed medication management device for transmitting the detected vital information via the wireless terminal. Detection report means for sending to the Internet to the address, medication control means for operating the medication mechanism in accordance with a medication instruction received from the Internet via the wireless terminal means to perform medication, and a statement to that effect after the execution of the medication. Medication reporting means for transmitting the medication to a predetermined medication management device via the wireless terminal to the Internet. A dispensing device according to claim.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001068526A JP2002263185A (en) | 2001-03-12 | 2001-03-12 | Medicine administration system and method and medicine administration device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001068526A JP2002263185A (en) | 2001-03-12 | 2001-03-12 | Medicine administration system and method and medicine administration device |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002263185A true JP2002263185A (en) | 2002-09-17 |
Family
ID=18926706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001068526A Pending JP2002263185A (en) | 2001-03-12 | 2001-03-12 | Medicine administration system and method and medicine administration device |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2002263185A (en) |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090614A1 (en) * | 2002-04-25 | 2003-11-06 | Matsushita Electric Industrial Co., Ltd. | Dosage determination supporting device, injector, and health management supporting system |
JP2004167120A (en) * | 2002-11-22 | 2004-06-17 | Kitakyushu Foundation For The Advancement Of Industry Science & Technology | Oral-installed biological monitor / therapy device |
WO2013070914A3 (en) * | 2011-11-09 | 2013-08-08 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US8542123B2 (en) | 2008-03-05 | 2013-09-24 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
US8540633B2 (en) | 2008-08-13 | 2013-09-24 | Proteus Digital Health, Inc. | Identifier circuits for generating unique identifiable indicators and techniques for producing same |
US8540664B2 (en) | 2009-03-25 | 2013-09-24 | Proteus Digital Health, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
US8545402B2 (en) | 2009-04-28 | 2013-10-01 | Proteus Digital Health, Inc. | Highly reliable ingestible event markers and methods for using the same |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
US8558563B2 (en) | 2009-08-21 | 2013-10-15 | Proteus Digital Health, Inc. | Apparatus and method for measuring biochemical parameters |
US8597186B2 (en) | 2009-01-06 | 2013-12-03 | Proteus Digital Health, Inc. | Pharmaceutical dosages delivery system |
US8674825B2 (en) | 2005-04-28 | 2014-03-18 | Proteus Digital Health, Inc. | Pharma-informatics system |
US8718193B2 (en) | 2006-11-20 | 2014-05-06 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
US8784308B2 (en) | 2009-12-02 | 2014-07-22 | Proteus Digital Health, Inc. | Integrated ingestible event marker system with pharmaceutical product |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US8858432B2 (en) | 2007-02-01 | 2014-10-14 | Proteus Digital Health, Inc. | Ingestible event marker systems |
US8868453B2 (en) | 2009-11-04 | 2014-10-21 | Proteus Digital Health, Inc. | System for supply chain management |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8932221B2 (en) | 2007-03-09 | 2015-01-13 | Proteus Digital Health, Inc. | In-body device having a multi-directional transmitter |
US8945005B2 (en) | 2006-10-25 | 2015-02-03 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
US8956288B2 (en) | 2007-02-14 | 2015-02-17 | Proteus Digital Health, Inc. | In-body power source having high surface area electrode |
US8956287B2 (en) | 2006-05-02 | 2015-02-17 | Proteus Digital Health, Inc. | Patient customized therapeutic regimens |
US8961412B2 (en) | 2007-09-25 | 2015-02-24 | Proteus Digital Health, Inc. | In-body device with virtual dipole signal amplification |
US9107806B2 (en) | 2010-11-22 | 2015-08-18 | Proteus Digital Health, Inc. | Ingestible device with pharmaceutical product |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US9268909B2 (en) | 2012-10-18 | 2016-02-23 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US9271897B2 (en) | 2012-07-23 | 2016-03-01 | Proteus Digital Health, Inc. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
KR20160088882A (en) * | 2013-11-22 | 2016-07-26 | 엠씨10, 인크 | Conformal sensor systems for sensing and analysis of cardiac activity |
US9597487B2 (en) | 2010-04-07 | 2017-03-21 | Proteus Digital Health, Inc. | Miniature ingestible device |
US9603550B2 (en) | 2008-07-08 | 2017-03-28 | Proteus Digital Health, Inc. | State characterization based on multi-variate data fusion techniques |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
US9883819B2 (en) | 2009-01-06 | 2018-02-06 | Proteus Digital Health, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
JP2018503904A (en) * | 2014-12-22 | 2018-02-08 | スミスズ メディカル エーエスディー,インコーポレイティド | Infusion planning system with clinical decision support |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
US10187121B2 (en) | 2016-07-22 | 2019-01-22 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
US10223905B2 (en) | 2011-07-21 | 2019-03-05 | Proteus Digital Health, Inc. | Mobile device and system for detection and communication of information received from an ingestible device |
US10398161B2 (en) | 2014-01-21 | 2019-09-03 | Proteus Digital Heal Th, Inc. | Masticable ingestible product and communication system therefor |
US10447347B2 (en) | 2016-08-12 | 2019-10-15 | Mc10, Inc. | Wireless charger and high speed data off-loader |
US10529044B2 (en) | 2010-05-19 | 2020-01-07 | Proteus Digital Health, Inc. | Tracking and delivery confirmation of pharmaceutical products |
US10567152B2 (en) | 2016-02-22 | 2020-02-18 | Mc10, Inc. | System, devices, and method for on-body data and power transmission |
US10761030B2 (en) | 2005-05-09 | 2020-09-01 | Labrador Diagnostics Llc | System and methods for analyte detection |
US10876956B2 (en) | 2011-01-21 | 2020-12-29 | Labrador Diagnostics Llc | Systems and methods for sample use maximization |
US10900958B2 (en) | 2007-10-02 | 2021-01-26 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US10986465B2 (en) | 2015-02-20 | 2021-04-20 | Medidata Solutions, Inc. | Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
US11139084B2 (en) | 2009-10-19 | 2021-10-05 | Labrador Diagnostics Llc | Integrated health data capture and analysis system |
US11149123B2 (en) | 2013-01-29 | 2021-10-19 | Otsuka Pharmaceutical Co., Ltd. | Highly-swellable polymeric films and compositions comprising the same |
US11162947B2 (en) | 2006-05-10 | 2021-11-02 | Labrador Diagnostics Llc | Real-time detection of influenza virus |
US11215610B2 (en) | 2006-10-13 | 2022-01-04 | Labrador Diagnostics Llc | Reducing optical interference in a fluidic device |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US11529071B2 (en) | 2016-10-26 | 2022-12-20 | Otsuka Pharmaceutical Co., Ltd. | Methods for manufacturing capsules with ingestible event markers |
US11612321B2 (en) | 2007-11-27 | 2023-03-28 | Otsuka Pharmaceutical Co., Ltd. | Transbody communication systems employing communication channels |
US11744481B2 (en) | 2013-03-15 | 2023-09-05 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
US11754554B2 (en) | 2007-08-06 | 2023-09-12 | Labrador Diagnostics Llc | Systems and methods of fluidic sample processing |
US11802882B2 (en) | 2006-11-14 | 2023-10-31 | Labrador Diagnostics Llc | Methods for the detection of analytes in small-volume blood samples |
US11992326B2 (en) | 2016-04-19 | 2024-05-28 | Medidata Solutions, Inc. | Method and system for measuring perspiration |
-
2001
- 2001-03-12 JP JP2001068526A patent/JP2002263185A/en active Pending
Cited By (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090614A1 (en) * | 2002-04-25 | 2003-11-06 | Matsushita Electric Industrial Co., Ltd. | Dosage determination supporting device, injector, and health management supporting system |
JP2004167120A (en) * | 2002-11-22 | 2004-06-17 | Kitakyushu Foundation For The Advancement Of Industry Science & Technology | Oral-installed biological monitor / therapy device |
US9161707B2 (en) | 2005-04-28 | 2015-10-20 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US9681842B2 (en) | 2005-04-28 | 2017-06-20 | Proteus Digital Health, Inc. | Pharma-informatics system |
US10517507B2 (en) | 2005-04-28 | 2019-12-31 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US10542909B2 (en) | 2005-04-28 | 2020-01-28 | Proteus Digital Health, Inc. | Communication system with partial power source |
US10610128B2 (en) | 2005-04-28 | 2020-04-07 | Proteus Digital Health, Inc. | Pharma-informatics system |
US9962107B2 (en) | 2005-04-28 | 2018-05-08 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US9649066B2 (en) | 2005-04-28 | 2017-05-16 | Proteus Digital Health, Inc. | Communication system with partial power source |
US9439582B2 (en) | 2005-04-28 | 2016-09-13 | Proteus Digital Health, Inc. | Communication system with remote activation |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8674825B2 (en) | 2005-04-28 | 2014-03-18 | Proteus Digital Health, Inc. | Pharma-informatics system |
US9119554B2 (en) | 2005-04-28 | 2015-09-01 | Proteus Digital Health, Inc. | Pharma-informatics system |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US11476952B2 (en) | 2005-04-28 | 2022-10-18 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
US8847766B2 (en) | 2005-04-28 | 2014-09-30 | Proteus Digital Health, Inc. | Pharma-informatics system |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8816847B2 (en) | 2005-04-28 | 2014-08-26 | Proteus Digital Health, Inc. | Communication system with partial power source |
US10761030B2 (en) | 2005-05-09 | 2020-09-01 | Labrador Diagnostics Llc | System and methods for analyte detection |
US11630069B2 (en) | 2005-05-09 | 2023-04-18 | Labrador Diagnostics Llc | Fluidic medical devices and uses thereof |
US10908093B2 (en) | 2005-05-09 | 2021-02-02 | Labrador Diagnostics, LLC | Calibration of fluidic devices |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US8956287B2 (en) | 2006-05-02 | 2015-02-17 | Proteus Digital Health, Inc. | Patient customized therapeutic regimens |
US11928614B2 (en) | 2006-05-02 | 2024-03-12 | Otsuka Pharmaceutical Co., Ltd. | Patient customized therapeutic regimens |
US11162947B2 (en) | 2006-05-10 | 2021-11-02 | Labrador Diagnostics Llc | Real-time detection of influenza virus |
US11442061B2 (en) | 2006-10-13 | 2022-09-13 | Labrador Diagnostics Llc | Reducing optical interference in a fluidic device |
US11215610B2 (en) | 2006-10-13 | 2022-01-04 | Labrador Diagnostics Llc | Reducing optical interference in a fluidic device |
US8945005B2 (en) | 2006-10-25 | 2015-02-03 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
US11357730B2 (en) | 2006-10-25 | 2022-06-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled activation ingestible identifier |
US10238604B2 (en) | 2006-10-25 | 2019-03-26 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
US11802882B2 (en) | 2006-11-14 | 2023-10-31 | Labrador Diagnostics Llc | Methods for the detection of analytes in small-volume blood samples |
US9083589B2 (en) | 2006-11-20 | 2015-07-14 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
US8718193B2 (en) | 2006-11-20 | 2014-05-06 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
US9444503B2 (en) | 2006-11-20 | 2016-09-13 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
US10441194B2 (en) | 2007-02-01 | 2019-10-15 | Proteus Digital Heal Th, Inc. | Ingestible event marker systems |
US8858432B2 (en) | 2007-02-01 | 2014-10-14 | Proteus Digital Health, Inc. | Ingestible event marker systems |
US11464423B2 (en) | 2007-02-14 | 2022-10-11 | Otsuka Pharmaceutical Co., Ltd. | In-body power source having high surface area electrode |
US8956288B2 (en) | 2007-02-14 | 2015-02-17 | Proteus Digital Health, Inc. | In-body power source having high surface area electrode |
US8932221B2 (en) | 2007-03-09 | 2015-01-13 | Proteus Digital Health, Inc. | In-body device having a multi-directional transmitter |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US10517506B2 (en) | 2007-05-24 | 2019-12-31 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US11754554B2 (en) | 2007-08-06 | 2023-09-12 | Labrador Diagnostics Llc | Systems and methods of fluidic sample processing |
US8961412B2 (en) | 2007-09-25 | 2015-02-24 | Proteus Digital Health, Inc. | In-body device with virtual dipole signal amplification |
US9433371B2 (en) | 2007-09-25 | 2016-09-06 | Proteus Digital Health, Inc. | In-body device with virtual dipole signal amplification |
US11899010B2 (en) | 2007-10-02 | 2024-02-13 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11199538B2 (en) | 2007-10-02 | 2021-12-14 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11366106B2 (en) | 2007-10-02 | 2022-06-21 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US10900958B2 (en) | 2007-10-02 | 2021-01-26 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11143647B2 (en) | 2007-10-02 | 2021-10-12 | Labrador Diagnostics, LLC | Modular point-of-care devices, systems, and uses thereof |
US11137391B2 (en) | 2007-10-02 | 2021-10-05 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11092593B2 (en) | 2007-10-02 | 2021-08-17 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11061022B2 (en) | 2007-10-02 | 2021-07-13 | Labrador Diagnostics Llc | Modular point-of-care devices, systems, and uses thereof |
US11612321B2 (en) | 2007-11-27 | 2023-03-28 | Otsuka Pharmaceutical Co., Ltd. | Transbody communication systems employing communication channels |
US9258035B2 (en) | 2008-03-05 | 2016-02-09 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
US8542123B2 (en) | 2008-03-05 | 2013-09-24 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
US8810409B2 (en) | 2008-03-05 | 2014-08-19 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
US9060708B2 (en) | 2008-03-05 | 2015-06-23 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
US11217342B2 (en) | 2008-07-08 | 2022-01-04 | Otsuka Pharmaceutical Co., Ltd. | Ingestible event marker data framework |
US10682071B2 (en) | 2008-07-08 | 2020-06-16 | Proteus Digital Health, Inc. | State characterization based on multi-variate data fusion techniques |
US9603550B2 (en) | 2008-07-08 | 2017-03-28 | Proteus Digital Health, Inc. | State characterization based on multi-variate data fusion techniques |
US8721540B2 (en) | 2008-08-13 | 2014-05-13 | Proteus Digital Health, Inc. | Ingestible circuitry |
US8540633B2 (en) | 2008-08-13 | 2013-09-24 | Proteus Digital Health, Inc. | Identifier circuits for generating unique identifiable indicators and techniques for producing same |
US9415010B2 (en) | 2008-08-13 | 2016-08-16 | Proteus Digital Health, Inc. | Ingestible circuitry |
US9883819B2 (en) | 2009-01-06 | 2018-02-06 | Proteus Digital Health, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
US8597186B2 (en) | 2009-01-06 | 2013-12-03 | Proteus Digital Health, Inc. | Pharmaceutical dosages delivery system |
US9119918B2 (en) | 2009-03-25 | 2015-09-01 | Proteus Digital Health, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
US8540664B2 (en) | 2009-03-25 | 2013-09-24 | Proteus Digital Health, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
US8545402B2 (en) | 2009-04-28 | 2013-10-01 | Proteus Digital Health, Inc. | Highly reliable ingestible event markers and methods for using the same |
US9320455B2 (en) | 2009-04-28 | 2016-04-26 | Proteus Digital Health, Inc. | Highly reliable ingestible event markers and methods for using the same |
US10588544B2 (en) | 2009-04-28 | 2020-03-17 | Proteus Digital Health, Inc. | Highly reliable ingestible event markers and methods for using the same |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
US8558563B2 (en) | 2009-08-21 | 2013-10-15 | Proteus Digital Health, Inc. | Apparatus and method for measuring biochemical parameters |
US11195624B2 (en) | 2009-10-19 | 2021-12-07 | Labrador Diagnostics Llc | Integrated health data capture and analysis system |
US11158429B2 (en) | 2009-10-19 | 2021-10-26 | Labrador Diagnostics Llc | Integrated health data capture and analysis system |
US11139084B2 (en) | 2009-10-19 | 2021-10-05 | Labrador Diagnostics Llc | Integrated health data capture and analysis system |
US8868453B2 (en) | 2009-11-04 | 2014-10-21 | Proteus Digital Health, Inc. | System for supply chain management |
US10305544B2 (en) | 2009-11-04 | 2019-05-28 | Proteus Digital Health, Inc. | System for supply chain management |
US9941931B2 (en) | 2009-11-04 | 2018-04-10 | Proteus Digital Health, Inc. | System for supply chain management |
US8784308B2 (en) | 2009-12-02 | 2014-07-22 | Proteus Digital Health, Inc. | Integrated ingestible event marker system with pharmaceutical product |
US10207093B2 (en) | 2010-04-07 | 2019-02-19 | Proteus Digital Health, Inc. | Miniature ingestible device |
US11173290B2 (en) | 2010-04-07 | 2021-11-16 | Otsuka Pharmaceutical Co., Ltd. | Miniature ingestible device |
US9597487B2 (en) | 2010-04-07 | 2017-03-21 | Proteus Digital Health, Inc. | Miniature ingestible device |
US10529044B2 (en) | 2010-05-19 | 2020-01-07 | Proteus Digital Health, Inc. | Tracking and delivery confirmation of pharmaceutical products |
US11504511B2 (en) | 2010-11-22 | 2022-11-22 | Otsuka Pharmaceutical Co., Ltd. | Ingestible device with pharmaceutical product |
US9107806B2 (en) | 2010-11-22 | 2015-08-18 | Proteus Digital Health, Inc. | Ingestible device with pharmaceutical product |
US11199489B2 (en) | 2011-01-20 | 2021-12-14 | Labrador Diagnostics Llc | Systems and methods for sample use maximization |
US10876956B2 (en) | 2011-01-21 | 2020-12-29 | Labrador Diagnostics Llc | Systems and methods for sample use maximization |
US11644410B2 (en) | 2011-01-21 | 2023-05-09 | Labrador Diagnostics Llc | Systems and methods for sample use maximization |
US11229378B2 (en) | 2011-07-11 | 2022-01-25 | Otsuka Pharmaceutical Co., Ltd. | Communication system with enhanced partial power source and method of manufacturing same |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
US10223905B2 (en) | 2011-07-21 | 2019-03-05 | Proteus Digital Health, Inc. | Mobile device and system for detection and communication of information received from an ingestible device |
KR20140092387A (en) * | 2011-11-09 | 2014-07-23 | 프로테우스 디지털 헬스, 인코포레이티드 | Apparatus, system, and method for managing adherence to a regimen |
KR102021475B1 (en) | 2011-11-09 | 2019-09-17 | 프로테우스 디지털 헬스, 인코포레이티드 | Apparatus, system, and method for managing adherence to a regimen |
WO2013070914A3 (en) * | 2011-11-09 | 2013-08-08 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
US9271897B2 (en) | 2012-07-23 | 2016-03-01 | Proteus Digital Health, Inc. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
US9268909B2 (en) | 2012-10-18 | 2016-02-23 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
US11149123B2 (en) | 2013-01-29 | 2021-10-19 | Otsuka Pharmaceutical Co., Ltd. | Highly-swellable polymeric films and compositions comprising the same |
US11744481B2 (en) | 2013-03-15 | 2023-09-05 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
US10421658B2 (en) | 2013-08-30 | 2019-09-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US10258282B2 (en) | 2013-11-22 | 2019-04-16 | Mc10, Inc. | Conformal sensor systems for sensing and analysis of cardiac activity |
JP2020142118A (en) * | 2013-11-22 | 2020-09-10 | エムシー10 インコーポレイテッドMc10,Inc. | Conformal sensor system for detection and analysis of cardiac activity |
JP7296344B2 (en) | 2013-11-22 | 2023-06-22 | メディデータ ソリューションズ インコーポレイテッド | Conformal sensor system for detection and analysis of cardiac activity |
KR20160088882A (en) * | 2013-11-22 | 2016-07-26 | 엠씨10, 인크 | Conformal sensor systems for sensing and analysis of cardiac activity |
KR102365120B1 (en) * | 2013-11-22 | 2022-02-18 | 메디데이타 솔루션즈, 인코포레이티드 | Conformal sensor systems for sensing and analysis of cardiac activity |
JP2017500093A (en) * | 2013-11-22 | 2017-01-05 | エムシー10 インコーポレイテッドMc10,Inc. | Conformal sensor system for detection and analysis of cardiac activity |
US10398161B2 (en) | 2014-01-21 | 2019-09-03 | Proteus Digital Heal Th, Inc. | Masticable ingestible product and communication system therefor |
US11950615B2 (en) | 2014-01-21 | 2024-04-09 | Otsuka Pharmaceutical Co., Ltd. | Masticable ingestible product and communication system therefor |
JP2020021517A (en) * | 2014-12-22 | 2020-02-06 | スミスズ メディカル エーエスディー,インコーポレイティド | Infusion planning system with clinical decision support |
JP2018503904A (en) * | 2014-12-22 | 2018-02-08 | スミスズ メディカル エーエスディー,インコーポレイティド | Infusion planning system with clinical decision support |
US10986465B2 (en) | 2015-02-20 | 2021-04-20 | Medidata Solutions, Inc. | Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
US10567152B2 (en) | 2016-02-22 | 2020-02-18 | Mc10, Inc. | System, devices, and method for on-body data and power transmission |
US11992326B2 (en) | 2016-04-19 | 2024-05-28 | Medidata Solutions, Inc. | Method and system for measuring perspiration |
US10797758B2 (en) | 2016-07-22 | 2020-10-06 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
US10187121B2 (en) | 2016-07-22 | 2019-01-22 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
US10447347B2 (en) | 2016-08-12 | 2019-10-15 | Mc10, Inc. | Wireless charger and high speed data off-loader |
US11529071B2 (en) | 2016-10-26 | 2022-12-20 | Otsuka Pharmaceutical Co., Ltd. | Methods for manufacturing capsules with ingestible event markers |
US11793419B2 (en) | 2016-10-26 | 2023-10-24 | Otsuka Pharmaceutical Co., Ltd. | Methods for manufacturing capsules with ingestible event markers |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002263185A (en) | Medicine administration system and method and medicine administration device | |
US12343495B2 (en) | Devices, systems, and methods for estimating active medication from injections | |
US12364822B2 (en) | Therapy management systems, methods, and devices | |
US11944465B2 (en) | Monitor user interface for diabetes management systems including flash glucose | |
US12208251B2 (en) | Pen cap for medication injection pen having temperature sensor | |
US11931549B2 (en) | User interface for diabetes management systems and devices | |
US20240350720A1 (en) | Pen cap for insulin injection pens and associated methods and systems | |
US20240293624A1 (en) | Insulin injection assistance systems, methods, and devices | |
US20030009088A1 (en) | Monitoring system for patients | |
US20130046279A1 (en) | User interface feature for drug delivery system | |
US20130046280A1 (en) | Drug delivery system with procedure stage based delivery adjustment | |
EP3207951B1 (en) | Automatic anesthesiology pump allowing improved anesthesiologist mobility | |
US12070328B2 (en) | Wearable personal healthcare sensor apparatus | |
US20230140188A1 (en) | Providing a visual representation of patient monitoring data | |
CN114641833A (en) | Providing a visual representation of patient monitoring data from a plurality of patient monitors | |
EP4428874A2 (en) | Devices, systems, and methods for estimating active medication from injections | |
EP3723696A1 (en) | User interface for diabetes management systems and devices | |
NZ601831B2 (en) | Docking station for patient bedside monitoring units | |
NZ601831A (en) | Docking station for patient bedside monitoring units |